Drug Profile
Tanimilast - Chiesi Farmaceutici
Alternative Names: CHF 6001 NEXThaler DPI; CHF 6001 NEXThaler®; CHF-6001; CHF6001 DPILatest Information Update: 22 Nov 2023
Price :
$50
*
At a glance
- Originator Chiesi Farmaceutici
- Developer Chiesi Farmaceutici; Chiesi USA
- Class Antiallergics; Antiasthmatics; Benzoates; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Phenyl ethers; Pyridines; Small molecules; Sulfonamides
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic obstructive pulmonary disease
- Phase II Allergic asthma
Most Recent Events
- 09 Sep 2023 Pharmacodynamics data from preclinical studies in Chronic obstructive pulmonary disorder presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
- 09 Sep 2023 Pharmacokinetics data from a phase I trial presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
- 09 Sep 2023 Pharmacodynamic data from a preclinical trial in Allergic asthma presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)